Sana Biotech Q2 2026: Net loss narrows to $63.6M; cash $160.5M, runway into mid-2027

Sana Biotechnology, Inc.

Q2 net loss $63.6M ($0.22/sh) vs $93.8M ($0.39) year ago; non-GAAP loss $39.7M ($0.13).
Cash, equivalents, marketable securities $160.5M at 6/30/26; raised $93.3M from ATM and Mayo Clinic's $25M equity investment.
SC451 IND and Phase 1/2 start expected as early as this year; SG293 first-in-human data expected as early as this year.
UP421 14-month data published in NEJM: C-peptide present, no immunosuppression, no safety issues.
Mayo Clinic collaboration to accelerate SC451 development; $25M equity investment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.